Moffitt Cancer Center Seeks Smokers Looking to Quit

March 11, 2015

TAMPA, Fla. Moffitt Cancer Center is seeking 80 tobacco smokers who are motivated to quit to take part in a new research study. The study aims to improve quit rates of smokers who use the medication, varenicline.  This prescription medication, sold under the brand name Chantix®, produces the highest smoking cessation rates of any of the FDA-approved smoking-cessation products. 

Participants will receive a medical screening and, if eligible for the study, receive a full course of varenicline (three months or more) at no cost, along with some personal smoking cessation counseling.  Each person will also receive compensation for their research-related time. 

Moffitt recently received a $397,000 grant from the Florida Department of Health via the James and Esther King Biomedical Research Program to study ways to improve the quit-rates of smokers using varenicline. This new study will compare different counseling components and dosing schedules of the medication.

Tobacco smoking is the leading preventable cause of cancer, responsible for about a third of all cancer deaths.  Therefore, as part of its mission to contribute to the prevention and cure of cancer, Moffitt is committed to developing better ways to help smokers quit.

For more information, interested smokers should call Moffitt’s Tobacco Research and Intervention Program at 813-745-1710.

About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. With more than 4,500 employees, Moffitt has an economic impact in Florida of nearly $1.6 billion. For more information, visit, and follow the Moffitt momentum on FacebookTwitter and YouTube.